Everotas 5mg (Everolimus)

Contact us for more information
Wishlist Compare
Brand nameEverotasInternational trade nameZortressActive substanceEverolimusStrength5mgCategoryAnti Cancer

Description  of  Everotas 5mg (Everolimus 5mg)

Everotas 5mg (Everolimus 5mg) is belongs to class of anti-cancer drugs Everotas 5mg (Everolimus 5mg) contains of an active compound known as Everolimus which is interfere with development of cancer cell and process is slows down. Everotas 5mg (Everolimus 5mg) tablets is not a curable medication, which is helps to slow their spreading into the body.

INDICATIONS of  Everotas 5mg (Everolimus 5mg)

The drug Everotas 5mg (Everolimus 5mg) is mainly used for the treatment of following disease • kidney carcinoma • Breast carcinoma • Brain carcinoma Everotas 5mg (Everolimus 5mg) is also used to treat in various advanced stage cancer in stomach, intestines or pancreas.

MECHANISM OF ACTION  of  Everotas 5mg (Everolimus 5mg)

Everolimus is an prohibitor of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis. Everotas 5mg (Everolimus 5mg)  also prohibits the expression of hypoxia-inducible factor, causing to a reduces in the expression of vascular endothelial growth factor. The results of everolimus prevention of mTOR is a reduction in cell multiplication, angiogenesis, and glucose uptake.

ABSORPTION OF ACTION  of  Everotas 5mg (Everolimus 5mg)

The time to peak plasma concentration of Everotas 5mg (Everolimus 5mg) occurs between 1 to 2 hours.

DISTRIBUTION OF ACTION  of  Everotas 5mg (Everolimus 5mg)

The drug Everotas 5mg (Everolimus 5mg) has Albumin human plasma protein bound of 74%.

METABOLISM OF ACTION  of  Everotas 5mg (Everolimus 5mg)

In hepatic Everotas 5mg (Everolimus 5mg) metabolism is take place, which is a substrate of CYP3A4. The Everotas 5mg (Everolimus 5mg) metabolism will occur through 3 processes; • Three monohydroxylated metabolite, • Two hydrolytic rings opened products, • Phosphatidylcholine conjugate of Everolimus.

ELIMINATION OF ACTION  of  Everotas 5mg (Everolimus 5mg)

The drug excretion primarily through 5% in urine; the parent compound has been detected in urine or feces. The drug half-life period is 30 hours.

 SIDE EFFECTS  of  Everotas 5mg (Everolimus 5mg)

• Thrombocytopenia
• Hypersensitivity reactions
• Hyperlipemia
• Angioedema
• Lymphomas & other malignancy
• Male infertility
• Proteinuria
• New commencement of diabetes
• Serious infections
• Kidney graft thrombosis
• Hepatic artery thrombosis
• Interstitial lung disease.

DRUG INTERACTION  of  Everotas 5mg (Everolimus 5mg)

Interaction of Everotas 5mg (Everolimus 5mg) with strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Concomitant use of Everotas 5mg (Everolimus 5mg) with strong CYP3A4 inducers, will increasing the disclosure of Everolimus. Interaction of Everotas 5mg (Everolimus 5mg) with cyclosporine will increasing the AUC level of Everolimus frequently. Interaction of ketoconazole with Everotas 5mg (Everolimus 5mg) tablet or other CYP3A4 inhibitors will increasing the plasma concentration and AUC of Everolimus. Combination of Everotas 5mg (Everolimus 5mg) with verapamil leads to increasing the plasma concentration of Everolimus. Interaction of Everotas 5mg (Everolimus 5mg) with Atorvastatin or pravastatin leads to rhabdomyolysis, due to increasing concentration of lipid lowering agents. When Everotas 5mg (Everolimus 5mg) combination with rifampicin will reduces the AUC of Everolimus

OVERDOSAGE  of  Everotas 5mg (Everolimus 5mg)

The over dosage of Everolimus is limited, If over dosage occurs patient must be provide with supportive measures. And monitor evidence of toxicity in Everolimus over dosage

PREGNANCY  of Everotas 5mg (Everolimus 5mg)


pregnancy category of everolimus c : in patients Everotas 5mg (Everolimus 5mg) is used only after knowing the benefits to the mother exceed the risk to fetus.

LACTATION  of Everotas 5mg (Everolimus 5mg)

Breast feeding should not be suggested

DOSAGE of  Everotas 5mg (Everolimus 5mg)

Everotas 5mg (Everolimus 5mg) tablets should be given with or without food. Dosage regimen of Everotas 5mg (Everolimus 5mg) ; In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer: The prescribed dosage is 10mg should be taken as a single dose. In Brain or intracranial cancer: The prescribed dosage of Everotas 5mg (Everolimus 5mg)  as a single dose. is 4.5mg/m2 given orally In pediatric: The pediatric dosage of Everotas 5mg (Everolimus 5mg)  as a single dose in brain or intracranial tumor is 4.5mg/m2 should be given orally.

STORAGE  of  Everotas 5mg (Everolimus 5mg)

Everotas 5mg (Everolimus 5mg) tablet store at 25℃ Protect the medicine away from moisture, heat and light.

MISSED DOSE of  Everotas 5mg (Everolimus 5mg)

if a single dose is missed, have the drug probably soon Next dose time reaches then leave the missed dose and continue the regular schedule Please consult with the doctor.

Brand name:
International trade name:
Active substance:
Anti Cancer
Intas Pharma
10 tablets
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India